Sanofi Total Non-Operating Income/Expense 2010-2024 | SNY
Sanofi annual/quarterly total non-operating income/expense history and growth rate from 2010 to 2024. Total non-operating income/expense can be defined as the sum of all non-operating expenses for the given industry.
- Sanofi total non-operating income/expense for the quarter ending September 30, 2024 was $-0.352B, a 77.63% increase year-over-year.
- Sanofi total non-operating income/expense for the twelve months ending September 30, 2024 was $-1.871B, a 202.59% decline year-over-year.
- Sanofi annual total non-operating income/expense for 2023 was $-1.852B, a 811.58% decline from 2022.
- Sanofi annual total non-operating income/expense for 2022 was $0.26B, a 141.98% decline from 2021.
- Sanofi annual total non-operating income/expense for 2021 was $-0.62B, a 0.05% decline from 2020.
Sanofi Annual Total Non-Operating Income/Expense
(Millions of US $) |
| 2023 |
$-1,852 |
| 2022 |
$260 |
| 2021 |
$-620 |
| 2020 |
$-620 |
| 2019 |
$-4,109 |
| 2018 |
$-1,030 |
| 2017 |
$-819 |
| 2016 |
$-1,309 |
| 2015 |
$-1,216 |
| 2014 |
$-916 |
| 2013 |
$-2,093 |
| 2012 |
$-989 |
| 2011 |
$-3,036 |
| 2010 |
$-3,061 |
| 2009 |
$-2,443 |
Sanofi Quarterly Total Non-Operating Income/Expense
(Millions of US $) |
| 2024-09-30 |
$-352 |
| 2024-06-30 |
$70 |
| 2024-03-31 |
$-71 |
| 2023-12-31 |
$-1,518 |
| 2023-09-30 |
$-198 |
| 2023-06-30 |
$-96 |
| 2023-03-31 |
$-40 |
| 2022-12-31 |
$2,157 |
| 2022-09-30 |
$-1,617 |
| 2022-06-30 |
$-192 |
| 2022-03-31 |
$-89 |
| 2021-09-30 |
$-93 |
| 2021-06-30 |
|
| 2021-03-31 |
$-148 |
| 2020-09-30 |
$-65 |
| 2020-03-31 |
$-163 |
| 2019-09-30 |
$-235 |
| 2019-03-31 |
$1 |
| 2018-03-31 |
$-70 |
| 2017-12-31 |
$-365 |
| 2017-09-30 |
$-200 |
| 2017-06-30 |
$-150 |
| 2017-03-31 |
$-106 |
| 2016-12-31 |
$-637 |
| 2016-09-30 |
$-326 |
| 2016-06-30 |
$-185 |
| 2016-03-31 |
$-161 |
| 2015-09-30 |
$-249 |
| 2015-06-30 |
$-48 |
| 2014-06-30 |
$-396 |
| 2013-06-30 |
$-840 |
| 2012-06-30 |
$-283 |
| 2012-03-31 |
$-315 |
| 2011-12-31 |
$-1,277 |
| 2011-09-30 |
$50 |
| 2011-06-30 |
$-722 |
| 2011-03-31 |
$-1,087 |
| 2010-12-31 |
$-1,705 |
| 2010-09-30 |
$-774 |
| 2010-06-30 |
$-288 |
| 2010-03-31 |
$-294 |
| 2009-12-31 |
$-403 |
| 2009-09-30 |
$-650 |
| 2009-06-30 |
$-1,331 |
| 2009-03-31 |
$-59 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$121.816B |
$46.611B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
